Literature DB >> 11156363

Pharmacodynamic monitoring of mycophenolate mofetil.

K Budde1, P Glander, S Bauer, K Braun, J Waiser, L Fritsche, I Mai, I Roots, H H Neumayer.   

Abstract

The immunosuppressive activity of Mycophenolate Mofetil (MMF) is based on the reversible inhibition of inosine-5'-monophosphate dehydrogenase (IMPDH) by mycophenolic acid. Pharmacodynamic monitoring by measurement of IMPDH activity reflects directly the biological response to MMF. For measurement of IMPDH activity in peripheral mononuclear cells we established a modified non-radioactive procedure, based on the incubation of cell lysates with inosine-5'-monophosphate and the chromatographic quantification of produced xanthosine-5'-monophosphate by isocratic ion-pair reversed phase HPLC. The between-run precision and within-run precision were 7% and 5%, respectively. We determined the time course of IMPDH activity in five patients after 1 g MMF and in five healthy subjects without administration of MMF. Additionally, IMPDH activity was determined in a population study of 40 healthy volunteers. In healthy volunteers, we observed a wide range of IMPDH activity (4.7-32.9 nmol/h/mg) with only weak diurnal variation. All patients receiving MMF had a significant reduction of IMPDH activity (65-100%) after administration of the drug. Inhibition persisted for up to 6 hours, and after 11 hours IMPDH activity returned to predose activities. The interindividual variability of IMPDH activity may account for pharmacodynamic differences in MMF-treated patients. Based on pharmacodynamic monitoring better dosing strategies for MMF-treated patients may evolve.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11156363     DOI: 10.1515/CCLM.2000.191

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  8 in total

1.  Pharmacodynamics of T-cell function for monitoring immunosuppression.

Authors:  M J Barten; A Tarnok; J Garbade; H B Bittner; S Dhein; F W Mohr; J F Gummert
Journal:  Cell Prolif       Date:  2007-02       Impact factor: 6.831

Review 2.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 3.  The compelling case for therapeutic drug monitoring of mycophenolate mofetil therapy.

Authors:  Guido Filler; Ana Catalina Alvarez-Elías; Christopher McIntyre; Mara Medeiros
Journal:  Pediatr Nephrol       Date:  2016-02-26       Impact factor: 3.714

Review 4.  Pharmacogenetics and immunosuppressive drugs in solid organ transplantation.

Authors:  Teun van Gelder; Ron H van Schaik; Dennis A Hesselink
Journal:  Nat Rev Nephrol       Date:  2014-09-23       Impact factor: 28.314

5.  An Update on Treatment of Pediatric Chronic Non-Infectious Uveitis.

Authors:  Arjun B Sood; Sheila T Angeles-Han
Journal:  Curr Treatm Opt Rheumatol       Date:  2017-01-29

Review 6.  To what extent does the understanding of pharmacokinetics of mycophenolate mofetil influence its prescription.

Authors:  Guido Filler; Nathalie Lepage
Journal:  Pediatr Nephrol       Date:  2004-07-15       Impact factor: 3.714

7.  Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy.

Authors:  Laurent R Chiarelli; Mariadelfina Molinaro; Carmelo Libetta; Carmine Tinelli; Laura Cosmai; Giovanna Valentini; Antonio Dal Canton; Mario Regazzi
Journal:  Br J Clin Pharmacol       Date:  2010-01       Impact factor: 4.335

8.  Developmental changes of MPA exposure in children.

Authors:  Elisa C Yoo; Ana Catalina Alvarez-Elías; Ekaterina Kirilova Todorova; Guido Filler
Journal:  Pediatr Nephrol       Date:  2016-01-07       Impact factor: 3.714

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.